In this study, we classified a large cohort of stage II and III GC patients who were managed with standard treatment into one of four TMITs, using immunohistochemical assessment of PD-L1 expression and CD8+ TIL infiltration as the surrogate markers of the tumor microenvironment (TME). The gene discussed is CD274; the disease is gastric cancer.